Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
Provectus (OTCQB: PVCT) has announced research advancements on its investigational immunotherapy PV-10 as an immune adjuvant aimed at enhancing vaccine efficacy against cancer and viruses. Recently, the USPTO published Provectus' patent application for using halogenated xanthenes in vaccines. In vitro data revealed that PV-10 significantly boosted interferon gamma-producing CD8 cells for Hepatitis B virus peptides. The company emphasizes its commitment to developing affordable immunotherapy medicines supported by this novel research.
- Patent application for halogenated xanthenes as vaccine adjuvants published by USPTO.
- In vitro studies indicate PV-10 significantly increases CD8 T cell response against Hepatitis B.
- Research supports the potential of PV-10 as an immune adjuvant to enhance vaccine effectiveness.
- None.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in vaccines for cancer and viruses to improve immune response upon vaccination, in conjunction with the Company’s ongoing efforts to expand its intellectual property.
On January 20, 2022, the U.S. Patent and Trademark Office (USPTO) published Provectus’ patent application entitled “Halogenated Xanthenes as Vaccine Adjuvants” (publication no. US 2022/0016242 A1), which contained among other things:
- In vitro data that showed PV-10 was able to significantly increase numbers of interferon (IFN) gamma-producing CD8 cells (compared to controls) for peptides representing various antigenic regions of the Hepatitis B virus (HBV) core protein (HBcAg). These peptides were selected for their capability to raise CD4 and CD8 T cells against HBV.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “Immune adjuvants can help vaccines generate quicker, more efficacious and durable immune responses. This new research further supports the multi-faceted immunogenicity of Provectus’ small molecule medical science platform, which is the foundation of our work to develop transformative, accessibly-priced immunotherapy medicines.”
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
Trademark
PV-10® is registered trademark of Provectus Pharmatech, Knoxville, Tennessee, U.S.A.
FORWARD-LOOKING STATEMENTS
The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Provectus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.
###
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
FAQ
What is the recent patent application published by Provectus related to?
What were the findings from Provectus' recent research on PV-10?
How does PV-10 aim to improve vaccine effectiveness?
What is the stock symbol for Provectus?
When was the patent application for halogenated xanthenes published?
